ABMI... Anyone else out there have this stock? LET'S TALK Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ABMI... Anyone else out there have this stock? LET'S TALK

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JBINWC who wrote (28)	12/26/1996 1:40:00 AM
From: John William Bowman	of 37

Hi all, This is off the Yahoo page about the clinical trials, sounds promising, maybe the worst is out of this stock, I am in for the long haul on this one. Have a great Holiday John Monday December 23 1:10 PM EDT American BioMed Inc. files IRB at UCLA to expand OmniCath clinical trials THE WOODLANDS, Texas--(BUSINESS WIRE)--Dec. 23, 1996--American BioMed Inc. (NASDAQ OTC BB:ABMI), Monday announced that it has filed an IRB at UCLA for OmniCath(r) atherectomy catheter for hemodialysis AV fistula restenosis and that IRB's will soon be filed at other sites. The company plans to file an IDE with the FDA for this indication by the end of December 1996. Industry analysts estimate the worldwide market potential for the AV fistula application at approximately $250-million. The company further announced that it has enrolled eight patients in its ongoing prospective randomized study comparing PTA to atherectomy (ongoing peripheral clinical trials). To date, the trials are progressing well and there have been no adverse effects or complications with any of the patients. As previously announced, the company has enrolled two more sites with Dr. Kim Hodgson at Southern Illinois University School of Medicine and Dr. Darwin Eaton at University of Southern California Medical Center for its peripheral clinical trials. Four additional sites are also being considered. The company's President and CEO, Steven B. Rash, stated: "These additional sites will accelerate our patient enrollment in our ongoing peripheral clinical trials as well as the AV fistula clinical trials which we expect to initiate in first quarter 1997. Our goal is to enroll 50 patients by June 1997 and complete the study by the end of 1997 for FDA approval for peripheral application. The company is very pleased with the progress of the OmniCath(r) clinicals to date and we are on schedule to obtain FDA approval which represents a major milestone in our efforts to commercialize our proprietary technology. The worldwide market potential for peripheral use is approximately $150-million." American BioMed Inc. utilizes state of the art technology to develop, manufacture and market minimally invasive medical, surgical and diagnostic devices which deliver unique advantages through advanced science. Over 25 patents cover its technologies competing in an industry with combined markets estimated at over $10-billion annually.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next